Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Ryan Jacobs et al.|Blood|2020Cited by 318
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Lindsey E. Roeker et al.|Clinical Cancer Research|2020Cited by 115
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R. Wilson, Fiona Miall, Toby A. Eyre et al.|UCL Discovery (University College London)|2022Cited by 76
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E. Roeker, Sigrid S. Skånland, Toby A. Eyre et al.|Blood|2021Cited by 70
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practiceElisabeth Schorb, Andrés J.M. Ferreri, Christopher P. Fox et al.|British Journal of Haematology|2020Cited by 69